![]() |
|
|
Vol. 285, Issue 2, 894-901, May 1998
Department of Biomedical Sciences, McMaster University (A.M.L., H.L.-C., C.Y.K., E.E.D.), Hamilton, ON L8N 3Z5, Canada and Research Service, (151), Edward Hines Jr. VA Hospital (R.D.B.), Hines, Illinois
| |
Abstract |
|---|
|
|
|---|
In this study, the effects of nine alpha-1 adrenoceptor antagonists [prazosin, WB 4101 (WB), chloroethylclonidine (CEC), 5-methylurapidil (5-MU), BMY 7378 (BMY), MDL 73005EF (MDL73), MDL 72832 (MDL72), RS 17053 (RS) and SK&F 105854 (SKF)] were studied on contractile responses to phenylephrine (PE) of the endothelium-denuded dog aorta in vitro. All antagonists, except CEC, 5-MU and RS, produced concentration-dependent competitive inhibition of contractile responses of the aorta to PE. The rightward shift of the concentration-response curves of PE yielded constant pKB values with increasing antagonist concentrations in most cases allowing a single pooled value to be determined: for prazosin, a pKB of 8.99 ± 0.11 (n = 20, KB of 1.03 nM); for WB, a pKB of 8.75 ± 0.08 (n = 23, KB of 1.76 nM); for BMY, a pKB of 7.21 ± 0.13 (n = 13, KB of 62 nM); for MDL72, a pKB of 7.95 ± 0.15 (n = 12, KB of 11.2 nM); and for SK&F 105854, a pKB of 5.82 ± 0.08 (n = 15, KB of 1.52 µM). For MDL73, pKB values decreased with antagonist concentration: 7.88 ± 0.06 at 10 nM, 7.56 ± 0.28 at 100 nM and 6.92 ± 0.18 at 1000 nM, which suggests the presence of more than one receptor subtype. CEC (10 and 100 µM) almost completely inhibited responses to PE; lower concentrations had no significant effect. 5-MU (10-300 nM) and RS (3-300 nM) were ineffective antagonists in this tissue. Because WB, a highly selective alpha-1D and alpha-1A adrenoceptor subtypes inhibitor, blocked PE responses (with less affinity than for alpha-1A adrenoceptors), and 5-MU and RS, which are selective blockers for alpha-1A adrenoceptor, were ineffective, we conclude that alpha-1A adrenoceptors are absent in the dog aorta. The effects of the less selective MDL72 were inconsistent with actions at alpha-1B or alpha-1D adrenoceptors. Although WB shifted the PE concentration-response curve to the right, the abilities of BMY, MDL73 and SKF to inhibit competitively PE contraction were of lower affinity compared with expectations for interaction with alpha-1D adrenoceptors; they are not the predominant subtype. The complete inhibition of PE responses by CEC suggests that the dog aorta contains the alpha-1B adrenoceptor subtype. In immunocytochemical studies of the expression of alpha-1B adrenoceptor, all cells apparently expressed this protein. Moreover, Western blot studies of the microsomal fractions confirmed the presence of alpha-1B adrenoceptors. In the dog aorta, the alpha-1 adrenoceptors predominantly resemble alpha-1B rather than alpha-1D adrenoceptors as reported in the rat aorta.
| |
Introduction |
|---|
|
|
|---|
Pharmacological,
radioligand binding and molecular studies have subclassified the
alpha-1 adrenoceptors into three subtypes, namely,
alpha-1A, alpha-1B and alpha-1D for
native receptors, and alpha-1a (historically,
alpha-1c), alpha-1b and alpha-1d
(historically, alpha-1a, alpha-1d or
alpha-1a/d) for cloned receptors (Hieble et al.,
1995a
). These subtypes can be identified with selective and
nonselective antagonists. For example, WB 4101 has high affinity for
alpha-1A as well as for alpha-1D (Saussy et
al., 1994
; Buckner et al., 1996
), 5-MU has high
affinity for alpha-1A, BMY 7378 (Saussy et al.,
1994
; Piascik et al., 1995
) and SK&F 105854 (Hieble et al., 1995a
, b
) have high affinity for alpha-1D and CEC
selectively inactivates alpha-1B and, to a lesser extent,
alpha-1D (see Hieble et al., 1995a
)
adrenoceptors. Subtypes of alpha-1 adrenoceptors also have
been classified by binding and pharmacological studies according to
high (pKD > 9) and low affinity
(pKD < 9) for prazosin (Muramatsu et
al., 1990
; Oshita et al., 1992
; Ford et
al., 1994
; Hieble et al., 1995a
). All the cloned
receptor subtypes correspond to those with high affinity.
Many studies have been conducted to identify alpha-1
adrenoceptor subtypes mediating vascular contraction in the rat aorta. Strong evidence, based on the effects of BMY 7375, WB 4101, 5-MU and
CEC, has been obtained arguing the predominant presence of the
alpha-1D subtype in the rat aorta (Saussy et al.,
1996
; Buckner et al., 1996
; Kenny et al., 1995
,
1996
). Other investigators have suggested that alpha-1B as
well as alpha-1D adrenoceptors also may be present (Van der
Graaf et al., 1996
). BMY administration in rats
competitively antagonized the PE-induced pressor response, which
suggests a role for alpha-1D adrenoceptors in the regulation of vascular resistance (Zhou and Vargas, 1996
). Molecular studies in
the rat aorta suggest that it transcribes the genes for
alpha-1b, alpha-1c (alpha-1a) and
alpha-1a/d adrenoceptor subtypes (Rokosh et al.,
1994
; Piascik et al., 1994
) to make mRNA. Whether all are
processed into expressed proteins is unclear.
In dog, density of plasma membrane
[3H]prazosin binding sites was three times
higher in the aorta than in the mesenteric artery, mesenteric vein and
saphenous vein (Shi et al., 1989
). Moreover, the
KD for [3H]prazosin
binding in the dog aorta was significantly lower than in the other
vessels (0.15 nM vs. 1-3 nM), which suggests the presence
of high-affinity prazosin (alpha-1) binding sites
(pKD of 9.82) (Shi et al., 1989
; Hoo
et al., 1994
). On the other hand, the densities of plasma
membrane [3H]rauwolscine binding sites in the
saphenous vein and the mesenteric vein were higher than in the aorta
and mesenteric artery. Hoo et al. (1994)
and Oriowa and
Ruffolo (1992)
have suggested that the alpha-1B adrenoceptor
subtype is present in the dog aorta, but the presence of
alpha-1D adrenoceptors remains to be assessed.
Recently, putative antagonists apparently having 50- to 100-fold
selectivity for alpha-1D have been reported (Hieble et
al., 1995a
, b
; Saussy et al., 1994
, 1996
). These are
BMY 7378 (BMY) and MDL 73005EF (Saussy et al., 1994
, 1996
;
Hieble et al., 1995a
[IUPHAR nomenclature, 7th edition])
and SK&F 105854 (SKF) (Hieble et al., 1995b
). Also a highly
selective antagonist against alpha-1A adrenoceptors, RS
17053 (RS) (Ford et al., 1996
), has been identified and an
antagonist potent against this receptor but more potent against a
presumptive new alpha-1 adrenoceptor, the 1L subtype (Testa
et al., 1995
, 1996
, 1997
; Leonardi, 1997
) has become
available. Because the alpha-2 adrenoceptor agonists were
unable to produce contractions, and because of the low density of
[3H]rauwolscine binding sites (Shi et
al., 1989
), we did not attempt to classify the alpha-2
adrenoceptors. In this study, we have characterized the pharmacological
profile of alpha-1 adrenoceptor subtypes in the dog aorta
with six antagonists against the various alpha-1
adrenoceptor subtypes. Our data indicate that two alpha-1 subtypes may be present in the dog aorta which resemble the
alpha-1B and alpha-1D adrenoceptors in the rat
aorta; however, the predominant receptor apparently is the
alpha-1B adrenoceptor. Expression of alpha-1B
adrenoceptors in this tissue was confirmed by immunocytochemical localization and Western blotting of microsomal membranes.
| |
Materials and Methods |
|---|
|
|
|---|
Animals and tissue preparation.
Mongrel dogs (10-30 kg)
were sacrificed by an overdose of sodium pentobarbital (100 mg·kg
1 i.v.), according to protocols
approved by the Animal Care Committee at McMaster University and
following the guidelines of the Canadian Council on Animal Care.
Contractility experiments. For muscle bath experiments, the dog aorta was removed and cleaned of surrounding tissue. A piece of the aorta was dissected open, and strips of the aorta were prepared by cutting along the perimeter of the aortic opened ring. These procedures usually resulted in tissues of 1 cm in length and about 2 mm in thickness. Tissue was dissected in a Petri dish filled with oxygenated Krebs' solution at 25°C. The composition of Krebs' solution in mM was: NaCl, 115; KCl, 4.9; MgCl2, 1.16; NaH2PO4, 1.10; NaHCO3, 21.9; CaCl2, 2.5; glucose, 11.0. The removal of endothelium by rubbing the luminal surface of the vessels was confirmed by the absence of carbachol (1 µM)-induced relaxation of precontractions produced by 60 mM K+.
The aortic tissues were suspended in a 10-ml organ bath containing Krebs' solution warmed to 37°C and bubbled with 95% O2 and 5% CO2. The preparations were allowed to equilibrate under an optimal initial resting tension of 15 g. Contractile responses were recorded on a polygraph (Beckman R611). The tissues were challenged with 100 mM K+ until reproducible contractions were attained. The contraction was considered to be reproducible if two consecutive contractions differed in tension by less than 10%. Except for CEC, all antagonists were added to the baths 30 min before the construction of concentration-response curves to PE. In experiments with CEC, 0.1 to 100 µM was incubated for 15 min at 37°C after which it and its hydrolysis products were removed by three washings before the construction of PE concentration-response curves.Data analysis. All contractile responses are expressed as a percentage of the contractile response to 100 mM K+ unless otherwise stated. Apparent KB values were calculated comparing the mean EC50 values of PE concentration-response curves (estimated for each curve using the logistic function in MicroCal Origin Software, Northampton, MA) to those from simultaneously studied controls. This was done because relaxation after PE-induced contraction in the dog aorta required prolonged washing of more than 60 min, precluding repetitive concentration-response curves. EC50 values were evaluated for the significance of differences with treatment with one-way analysis of variance. Data from determinations of KB values were expressed as pKB and standard errors and significance of differences between values at different antagonist concentrations determined. Statistical significance was accepted at P values of less than .05. When pKB values across a range of several antagonist concentrations were not significantly different, the values were pooled. Data are expressed as means ± S.E.M.
Immunocytochemical studies.
Four healthy dogs of either sex
were sacrificed and blood vessels collected from aorta and mesenteric
arteries as described above. Blood vessels were opened, rinsed free of
blood and pinned out on Sylgard silicon rubber-coated dishes and fixed
with 4% paraformaldehyde with 0.1 M phosphate buffer, pH 7.4. The
tissues to be used for cryostat sectioning were cut into small pieces and then stored in 15% sucrose containing phosphate-buffered saline for cryoprotection at 4°C for 24 hr and sectioned in 16-µm
thicknesses in a cryostat (Leitz 1720 digital). The sections were
collected on the slides coated with gelatin. Cryostat sections were
incubated overnight at 4°C in 1:300 dilutions of rabbit antisera
raised against residues 506-515 at the carboxyl terminus of the
hamster alpha-1B adrenoreceptor which had been coupled to
keyhole limpet hemocyanin (Fonseca et al., 1995
, 1997
).The
antibody was visualized with CY3 labeled goat anti-rabbit goat
anti-mouse antibodies (Jackson ImmunoResearch, West Grove, PA).
Specificity of staining was ascertained with preimmune serum and by
saturation of the antibody with the peptide epitope against which it
was raised (5 µg/ml) during exposure of cryostat sections. Background
and autofluorescence was evaluated by omission of the primary antibody.
After washing with phosphate-buffered saline, the sections were then
mounted in 80% glycerol in phosphate-buffered saline (pH 10) and
viewed on a Leitz microscope equipped with fluorescence epiluminator
and I2 filter. Kodak T-MAX 400 film was used for
black and white photography.
Western blotting.
Plasmalemma-enriched microsomal membrane
fractions used for Western blotting studies were isolated from dog
aortic smooth muscle layers according to fractionation procedures
previously developed and characterized in this laboratory (Kwan
et al., 1984
). Mic I fraction represents the
postmitochondrial fraction 4- to 6-fold enriched in plasmalemma content
over the postnuclear supernatent, and Mic II fraction represents
further a refined fraction from Mic I with plasmalemma content twice
that in Mic I. Postnuclear supernatent membranes were prepared from rat
spleen, as a tissue source of alpha-1B adrenoceptors (Hoo
et al ., 1994
).
Drugs. Unless otherwise stated, the drugs were dissolved in double distilled, deionized water. L-phenylephrine (Sigma, ST. Louis, MO), WB 4101 (2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride (Research Biochemicals Inc. [RBI], Natick, MA), BMY 7378 (8-(2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl)-8-azaspiro[4,5]decane-7,9-dione dihydrochloride, RBI), MDL 72832, {8-[4-(1,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspirol[4,5]decane-7,9-dione HCl and MDL 73005EF, {8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspirol[4,5]decane-7,9-dione HCl (Tocris Cookson Chemicals, Bristol, UK), prazosin (dissolved in dimethyl sulfoxide to a stock of 10 mM and protected from light, Sigma) and chloroethylclonidine dihydrochloride (CEC, RBI). SK&F 105854 was a generous gift from Dr. J.P. Hieble (SmithKline Beecham Pharmaceuticals, King of Prussia, PA).
| |
Results |
|---|
|
|
|---|
Effects of prazosin on PE concentration-response curves.
The
aortic strips were treated with prazosin, a poorly selective
alpha-1 antagonist, at 10, 30 and 100 nM before cumulative additions of PE to construct a concentration-response curve (fig. 1, table
1). In tissues treated with prazosin,
rightward shift of PE concentration-response curves was indicated by
the EC50 values of PE. The
pKB values for concentrations of prazosin of 10
8, 3 × 10
8 and 10
7 M
were not significantly different (8.98 ± 0.22, n = 7; 9.02 ± 0.16, n = 7; and 8.95 ± 0.23, n = 6), equivalent to a Schild plot slope not different
from 1, so these values were pooled and a mean
pKB of 8.99 ± 0.11, n = 20 (KB = 1.03 nM) for prazosin was obtained.
|
|
Effects of WB 4101 on PE concentration-response curves.
WB
4101, which has high affinity for alpha-1A and
alpha-1D, shifted PE concentration-response curves in dog
aorta as shown in figure 2. At 10, 30 and
100 nM, WB 4101 affected EC50 values of PE
concentration-response curves (table 1) with pKB
values of 8.80 ± 0.10, n = 8; 8.81 ± 0.20, n = 8; and 8.65 ± 0.10, n = 7, respectively. These were not significantly different, and a Schild
slope was not different from 1, so the data were pooled with a
resultant pKB value for WB 4101 of 8.75 ± 0.08 (n = 23) and KB = 1.76 nM. The value suggests the dog aorta alpha receptors have an
affinity for WB 4101 that is intermediate between alpha-1A or alpha-1D adrenoceptors (pKB > 9)
and alpha-1B adrenoceptors (pKB
8) [see Saussy et al. (1996)
and Ford et al
. (1994)
].
|
Effects of CEC on PE concentration-response curves.
Chloroethylclonidine irreversibly inactivates alpha-1B and a
large fraction of alpha-1D adrenoceptors. It also can
inactivate some alpha-2 adrenoceptors and can interact
competitively with other alpha subtypes (Michel et
al., 1993
; Low et al., 1994
; Nunes and Guimaraes,
1993
). In the dog aorta, low concentrations of CEC (fig.
3; table 1) (100, 300 and 1000 nM) had no
functional effect on PE concentration-response curves. However, higher
concentrations (10 and 100 µM) of CEC noncompetitively, irreversibly
and almost completely abolished PE responses.
|
Effects of 5-MU on PE concentration-response curves. The antagonist 5-MU discriminates between alpha-1A and alpha-1D adrenoceptor subtypes with high affinity only for the alpha-1A subtype. In the dog aorta, 5-MU at concentrations of 10, 30, 100 and 300 nM did not significantly alter the concentration-response curves to PE (fig. 4; table 1).
|
Effects of RS 17053 on PE concentration-response curves.
A
recently described antagonist (Ford et al., 1996
; Lachnit
et al., 1997
), RS 17053, also was reported to be highly
selective for alpha-1A adrenoceptors but to have lower
affinity for the putative alpha-1L subtype. It, like 5-MU,
had no effect on concentration-response curves of the dog aorta to PE
(fig. 5). For concentrations of RS 17053 of 3, 30 and 300 nM, the dose ratios (treated/control) from
EC50 values were not significantly different from
one: 1.13 ± 0.41, 1.26 ± 0.31 and 1.63 ± 0.27, respectively (mean ± S.E.M., n = 4).
|
Effects of MDL 72832 on PE concentration-response curves.
MDL
72832 also is considered a somewhat selective alpha-1A
adrenoceptor antagonist, based on binding affinities for expressed receptors (Saussy et al., 1996
). It shifted the PE
concentration-response curve rightward at 10, 100 or 1000 nM with
pKB values of 7.83 ± 0.26, 7.93 ± 0.07 and 8.10 ± 0.41 (mean ± S.E.M., n = 4), respectively, yielding a pooled value of 7.95 ± 0.15 (mean ± S.E.M., n = 12) with
KB of 11.2 nM. These
pKB values were too low to be consistent with the
presence of alpha-1A adrenoceptors (expected values, 8.4-8.6) and did not distinguish alpha-1B from
alpha-1D subtypes.
Effects of BMY 7378 on PE concentration-response curves.
BMY
7378, a selective alpha-1D antagonist, at concentrations of
100, 300 and 1000 nM, gave pKB values of
7.13 ± 0.22 (n = 3), 7.07 ± 0.15 (n = 6) and 7.45 ± 0.28 (n = 4),
respectively. The three mean pKB values were not
significantly different, so these data were pooled, resulting in a
pooled pKB of 7.21 ± 0.13 (n = 13) with KB = 62 nM
(fig. 6; table 1). This
pKB value was much less than that reported in rat
aorta, 8.88, or the pKi value for the human
alpha-1D adrenoceptor, 9.39, and close to the
pKi for the human alpha-1B
adrenoceptor, 7.25 (Saussy et al., 1996
)
|
Effects of MDL 73005EF on PE concentration-response curves.
MDL 73005EF also was reported to be a alpha-1D adrenoceptor
selective antagonist (Saussy et al., 1996
). At
concentrations of 10, 100 and 1000 nM, it caused rightward shifts of
concentration-response curves. However, the calculated
pKB values decreased significantly with
antagonist concentrations. At 10, 100 and 1000 nM the respective values
were: 7.88 ± 0.06, 7.56 ± 0.28 and 6.92 ± 0.18 (corresponding to KB values of 13.2, 27.5 and 120.2 nM). In rat aorta, the pKB value for
this compound was 8.00, corresponding to a pKi
value for the expressed human alpha-1D adrenoceptor of 8.16 (Saussyet al., 1996
). Thus for all but the lowest
concentration, the pKB values were too low for
alpha-1D adrenoceptors, but appropriate at higher
concentrations for alpha-1B adrenoceptors
(pKi = 6.88 for the expressed human receptor).
Effects of SK&F 105854 on PE concentration-response curves. Concentration-response curves to PE were constructed in the absence and in the presence of SK&F 105854, a putative, selective alpha-1D antagonist. The pKB values calculated for the four SKF concentrations used were not significantly different from each other [5.95 ± 0.33 (n = 3), 5.68 ± 0.10 (n = 4), 5.90 ± 0.12 (n = 4) and 5.78 ± 0.16 (n = 4) for SKF concentrations of 1, 3, 10 and 30 µM, respectively], so these pKB values were pooled to give a value of 5.81 ± 0.08 with KB = 1.52 µM (n = 15) (see fig. 7; table 1).
|
Immunocytochemistry of alpha-1B adrenoceptors in dog
aorta.
Studies in dog mesenteric artery strongly suggest that it
contains predominantly alpha-1A or alpha-1L
adrenoceptors and few or no alpha-1B adrenoceptors (Daniel
EE, Lu-Chao H, Low AM, Brown RD and Kwan CY, unpublished). Therefore,
staining with an antibody for alpha-1B adrenoceptors was
compared in mesenteric artery and aorta. As reported elsewhere,
mesenteric artery smooth muscle did not recognize an antibody against
an epitope exclusive to the alpha-1B adrenoceptor (Fonseca
et al., 1995
). However, as shown in figure
8, the aorta stained strongly and all
cells were stained. In 15-µm-thick sections the staining appeared to
encompass the entire cell except in cells cross-sectioned through the
nucleus (fig. 8A). However, when cell edges were cut tangentially the staining appeared to be particulate. This figure shows that all cells
within bundles were immunostained, a uniform finding whether tissues
were cut in cross-sections (fig. 8A) or in longitudinal sections (fig.
8B). The preimmune serum did not immunostain aorta smooth muscle (fig.
8, C and D), and saturation of the antibody with 5 µg/ml of the
peptide antigen used to raise the antibody nearly abolished staining
(fig. 8E), leaving only nonspecific staining such as produced after
omission of the primary antibody (fig. 8F),
|
Western blot of aortic microsomal membranes. Mic I and Mic II membranes were studied and immunoblotted with immune serum, preimmune serum and immune serum after preabsorption with the peptide used to raise the antibody. Other microsomal membranes from mesenteric artery (DMA) and rat spleen (RSP) also were used for comparison. As expected, a protein with a molecular weight about 80 kdaltons was found in aortic membranes, more densely present in Mic II than Mic I membranes (fig. 9, lanes 1 and 2). Exposure of the blots to the preimmune serum (lanes1a and 2a) or the immune serum after saturation with 0.2 µg/ml of peptide antigen (not shown) did not lead to staining. Staining of a protein of the same molecular weight was found in membranes from rat spleen in which the alpha-1B receptor was expressed (lane 4), but no expression was found in mesenteric artery membranes (lanes 3), which we have found to contain mostly alpha-1A adrenoceptors (Daniel et al., unpublished). In no case was there staining by preimmune serum.
|
| |
Discussion |
|---|
|
|
|---|
Molecular pharmacology studies in rats and humans have
demonstrated the expression of three subtypes of alpha-1
adrenoceptors (see Hieble et al., 1995a
) but have not
provided any information about the relative contribution of each
receptor subtype to the behavior of whole tissue, such as blood
vessels. Pharmacological classification of alpha
adrenoceptor subtypes evolved along with the discovery of subtypes and
the availability of pharmacological antagonists. In this study we used
a panel of nine different alpha-1 adrenoceptor antagonists
to classify the subtypes of alpha-1 adrenoceptor that are
present in the endothelium-denuded dog aorta. Our evidence suggests
that the smooth muscle of dog aorta contains mainly alpha-1B adrenoceptors but some alpha-1D adrenoceptors also may be
present.
It has been postulated that all three subtypes, which have high
affinity (pKD > 9) in binding studies for both
prazosin and HV-723, are members of the alpha-1H
adrenoceptor family (Muramatsu et al., 1990
; Oshita et
al., 1992
; Ford et al., 1994
). Our previous radioligand
studies showed high-affinity [3H]prazosin
binding in the dog aorta (Shi et al., 1989
; Hoo et al., 1994
) with a pKD of 9.8. This value is
somewhat higher than the pKB value, 9.0, but is
consistent with the demonstration of a high correlation between binding
interactions of alpha-1 adrenoceptors in canine aorta and
binding to recombinant alpha-1b adrenoceptors recently
reported by Leonardi et al. (1997)
. The mechanism of the
approximate one log unit discrepancy between prazosin affinities in
ligand binding and in functional studies is unclear but possibly may be
related to the different experimental conditions (Grever et
al., 1997
; Jasper et al., 1997
; Michel et
al., 1997
). However, the lower affinity for prazosin from
functional studies cannot be attributed to uptake of agonist into nerve
terminals because synthetic PE was used instead of noradrenaline.
Furthermore, the dog aorta is sparsely innervated by adrenergic nerves
if innervated at all (Kwan et al., 1984
). Moreover,
phenylephrine has minimal low-affinity interactions with
alpha-2 or
-adrenoceptors. There are few functional
studies in which pKB values near 10 for prazosin are found; e.g., in the recent study of Leonardi et
al. (1997)
interactions between prazosin and rabbit urethra,
prostate, aorta and ear artery all yielded pKB
values between 7.85 and 8.82; the last value was from the aorta.
Therefore, it is possible that the higher affinity values reflect the
conditions of binding studies which differ from conditions of
functional studies.
Our studies revealed no evidence for the presence of
alpha-1A adrenoceptors. Two highly selective antagonists,
5-MU and RS 17053, had no significant antagonistic effects in
concentrations which should have markedly inhibited responses. Although
less selective, another antagonist, MDL 72832, also failed to suggest the presence of appreciable numbers of these receptors, because the
pKB values were equally consistent with the
presence of alpha-1B adrenoceptors. In studies to date
antagonists effective against alpha-1A adrenoceptors also
have had some potency against the putative alpha-1L subtype
(Leonardi et al., 1997
). Thus they are also unlikely to be
functional in this blood vessel. If alpha-1A and
alpha-1L adrenoceptors are functionally absent from the dog aorta, then only alpha-1B or alpha-1D
adrenoceptors or both must mediate contraction.
With use of the alkylating agent CEC to irreversibly inactivate the
alpha-1B adrenoceptors, Hoo et al. (1994)
reported that CEC pretreatment (30 min, 4°C, 100 µM) reduced
[3H]prazosin binding sites by about 75% and
suggested that the dog aorta contains mainly alpha-1B
adrenoceptors. Subsequently, the selectivity of CEC for
alpha-1B adrenoceptors has been questioned (see Hieble
et al., 1995a
; Michel et al., 1993
). Our present
functional study supports the presence of the alpha-1B
adrenoceptors in the dog aorta, which are sensitive to CEC and
relatively insensitive to antagonists, BMY 7378, MDL 73005EF and SK&F
105854, alpha-1D selective in rodents and humans. In this
study, the pKB for BMY was 6.95, which is a lower
value than reported by Saussy et al. (1996)
for human
recombinant alpha-1D expressed in rat fibroblasts (9.39) and
in rat aorta (8.88), a tissue which demonstrates predominance of the
alpha-1D subtype. The pKi value for
BMY with human alpha-1B adrenoceptors expressed in
fibroblasts was 7.25, close to the value we observed, but clearly not
different from the value for the expressed human alpha-1A
adrenoceptor of 6.8. The pKB values for MDL
73005EF, a structural analog of BMY, decreased with concentration from
7.88 to 6.92. This compound had a pKB in rat
aorta of 8.00 and a pKi of 8.16 for the human
alpha-1D adrenoceptor (Saussy et al., 1996
). Thus
our values were also inconsistent with the predominant receptor in
canine aorta. At low concentrations, the value was consistent with the
pKi of the human alpha-1D
adrenoceptor, but at higher concentrations the values were similar to
those of the human alpha-1B adrenoceptor (6.88). Although
our value for the pKB of SK&F 105854 (5.82) is
similar to the pKB (5.77) reported by Hieble
et al. (1995b)
in rat aorta, both values are lower than that
for recombinant receptors at alpha-1D adrenoceptors (pKi = 7.14) and closer to the values for
alpha-1B or alpha-1A adrenoceptors
(pKi values of 6.11 and 5.48, respectively).
Thus, the inappropriately low affinities which we observe for
alpha-1D selective antagonists argue that the CEC-sensitive
contractions in dog aorta are subserved mainly by alpha-1B,
rather than the alpha-1D, subtype. However, our results
allow the presence of a population of alpha-1D adrenoceptors
as well.
The reported affinities of WB 4101 for alpha-1 adrenoceptor,
pKi values of 8.71 and 9.76 for rat
alpha-1D and alpha-1A adrenoceptors, respectively, and pKi values of 9.33, 9.54 and
8.62 for human
1D,
1A and
1B
adrenoceptors, respectively (Saussy et al., 1996
), compared
with the pKB of 8.6 observed for dog aorta
alpha-1 adrenoceptors in this study, are consistent with the
possibility that alpha-1B or alpha-1D subtype
receptors are indeed present in the dog aorta. Moreover, WB 4101 was
reported to inhibit competitively [3H]prazosin
binding in both control and CEC-treated membranes (Hoo et
al., 1994
) as expected if the residual alpha
adrenoceptors sensitive to WB 4101 after CEC alkylation are the
alpha-1D subtype. The proposal that WB 4101 acts on
alpha-1B/D adrenoceptors rather than on alpha-1A
subtypes would explain the lack of effect of 5-MU or RS17053 and the
low potency (pKB, 7.15, compared with pKi values of 8.6 or 8.4 for rat and human
alpha-1A adrenoceptors) of MDL 72832 observed in this study.
Thus all the functional evidence is consistent with the premise that
alpha-1B adrenoceptors are present and predominantly determine the functional responses of this tissue. This evidence was
strongly supported by the Western blot studies which showed a protein
of the appropriate molecular weight in aortic plasmalemma as well as in
membranes from a cell line in which the receptor was expressed, which
was recognized by an antibody against an epitope of the
alpha-1B adrenoceptor (Fonseca et al., 1995
). The specificity of this recognition was shown by the absence of recognition by preimmune serum, by the ability of the epitope peptide to abolish staining and by the absence of staining in membranes of mesenteric artery which lacks functional evidence of the alpha-1B
adrenoceptor. The questions remain, is there an additional receptor in
the aorta and how is the alpha-1B adrenoceptor distributed?
If there are both alpha-1B and alpha-1D
adrenoceptors on the dog aorta, then an important question is whether
they are distributed as a cellular mosaic with some cells exclusively
containing each subtype, or as a subcellular mosaic with each cell
having some of each subtype? The antibody to the alpha-1B
adrenoceptor subtype which recognized the alpha-1B
adrenoceptor in Western blots of plasmalemma was also active in
immunocytochemical studies (Fonseca et al., 1995
). This
enabled us to approach this question and to provide further
substantiation for the predominance of alpha-1B adrenoceptors. Our studies showed that all smooth muscle cells were
immunoreactive to the antibody for alpha-1B subtype
adrenoceptors, which suggests that, if a mosaic exists, it is
subcellular in distribution. The strong staining obtained suggests that
the major receptor subtype expressed in canine aorta is
alpha-1B. In this regard, we note that alpha-1B
adrenoceptor immunostaining presents a nonuniform or punctate
appearance in some cellular profiles, which suggests that receptors may
localize to distinct subcellular structures. An antibody specific for
alpha-1D adrenoceptors and functional in immunocytochemistry
is not available, so we could not test the presence and distribution of
alpha-1D adrenoceptors with this technique. The antibody
that recognized alpha-1B adrenoceptor also recognized a
protein in Western blot studies of ~80 kdaltons molecular weight,
near the value reported for alpha-1B adrenoceptors (Fonseca
et al., 1995
).
In conclusion, the dog aorta smooth muscle exhibits predominantly
functional alpha-1B-like adrenoceptor activities.
Immunocytochemical data support strong prominent expression of
alpha-1B adrenoceptors throughout this vessel. The
functional activities of the subtype found in canine aorta correspond
to previously reported high-affinity [3H]prazosin binding sites in the same tissue
(Shi et al., 1989
; Hoo et al., 1994
) with a
reported pKD of 9.82 for prazosin. Our conclusions are similar to those of Leonardi et al. (1997)
in which binding to canine aortic adrenoceptors correlated highly with
binding to recombinant alpha-1b adrenoceptors. There may be
additional receptors of the alpha-1D subtype, but so far the uncloned alpha-1L adrenoceptors, as suggested by Leonardi
et al. (1997)
, are unlikely to be present.
| |
Acknowledgments |
|---|
The authors are grateful to J. Loke for editorial assistance.
We are also grateful to Mr. Tony Kwan and Ms. Angela Demeter for their excellent technical assistance and computer analysis of data.
| |
Footnotes |
|---|
Accepted for publication January 30, 1998.
Received for publication August 21, 1997.
1 Supported by the Heart and Stroke Foundation of Ontario.
2 Recipient of the Career Investigator award of the Heart and Stroke Foundation of Ontario.
Send reprint requests to: E.E. Daniel, PhD, Professor Emeritus, Room 4N51, Department of Biomedical Sciences, McMaster University, Hamilton ON L8N 3Z5, Canada.
| |
Abbreviations |
|---|
BMY, BMY 7378 or
{8-(2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl)-
8-azaspirol[4,5]decane-7,9-dione ;
Bmax, maximum concentration of bound ligand per mg membrane protein;
CEC, chloroethylclonidine;
DMA, dog mesenteric artery;
EC50, concentration for 50% maximum response;
IC50, 50%
inhibitory concentration;
KB, calculated
antagonist dissociation constant in functional studies;
KD, dissociation constant in saturation
ligand binding studies;
Ki, dissociation
constant in competition ligand binding studies;
MDL72, MDL 72832, {8-[4-(1,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspirol[4,5]decane-7,9-dione
HCl ;
MDL73, MDL 73005EF,
{8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspirol[4,5]decane-7,9-dione
HCl ;
MIC2, microsomal fraction used for binding;
RS, RS-17053 or
N-[2-(-cyclopropyl methoxy phenoxy) ethyl]-5-chloro-
,
-dimethyl-1H-indole-3-ethanamine HCl ;
SKF, SK&F 105854 or
7-chloro-2-bromo-3,4,5,6-tetrahydro-4-methylfurol[4,3,2-ef]-3
benzapine;
WB, WB 4101 or
2-(2,6-dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane;
5-MU, 5-methylurapidil;
PE, phenylephrine.
| |
References |
|---|
|
|
|---|
1-Adrenoceptor-induced contractility in rat aorta is mediated by the
1D subtype.
Eur J Pharmacol
297:
241-248[Medline].
1A-adrenoceptor antagonist, displays low affinity for functional
1-adrenoceptors in prostate of man: implications for receptor classification.
Mol Pharmacol
49:
209-215[Abstract].
1-Adrenoceptors classification: sharpening Occam's razor.
Trends Pharmacol Sci
15:
167-170[Medline].
1A-adrenoceptor expressed in Chinese hamster ovary cells (CHO-K1) (abstract).
The Pharmacologist
39:
43.
1-adrenoceptors: Consensus update.
Pharmacol Rev
47:
267-270[Medline].
2-adrenoceptors.
Pharmacol Commun
6:
91-97.
1-adrenoceptor subtypes in canine aorta, using alkylating agents.
Can J Physiol Pharmacol
72:
97-103[Medline].
1A-adrenoceptor isoforms in membranes and whole cells (abstract).
The Pharmacologist
39:
39.
1D adrenoceptor mediating the contractile response of rat aorta to noradrenaline.
Br J Pharmacol
115:
981-986[Medline].
1 adrenoceptor antagonists at prostatic
1 adrenoceptors: binding, functional and in vivo studies.
Br J Pharmacol
118:
871-878[Medline].
1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat.
Br J Pharmacol
120:
819-826[Medline].
1-adrenoceptor subtypes mediating vasoconstriction in mice (abstract).
The Pharmacologist
39:
44.
1- and
2-adrenoceptor subtypes.
Mol Pharmacol
44:
1165-1170[Abstract].
1-adrenoceptors in vascular smooth muscle.
Br J Pharmacol
99:
187-201.
2-adrenoceptors in the dog saphenous vein.
Naunyn-Schmiedeberg's Arch Pharmacol
348:
264-268[Medline].
1-adrenoceptors in mammalian aortae: subclassification based on chloroethylclonidine, WB 4101 and nifedipine.
J Vasc Res
29:
33-40[Medline].
1-Adrenoceptor subtypes in rabbit thoracic aorta. Jpn
J Pharmacol 58:suppl II, 276P.
1D adrenoceptor to the contraction of vascular smooth muscle.
J Pharmacol Exp Ther
275:
1583-1589
1D-adrenoceptor and two other
1-adrenoceptors in vascular smooth muscle.
Mol Pharmacol
46:
30-40[Abstract].
1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with
1B and
1D.
Biochem Biophys Res Commun
200:
1177-1184[Medline].
1D adrenoceptors (AR):Evidence
that rat vascular
1 AR are of the
1D
subtype. Can J Physiol Pharmacol 72:suppl 1, 323.
1 adrenoceptors: further evidence that rat aorta
1 adrenoceptors are of the
1D-subtype.
J Pharmacol Exp Ther
278:
136-144
adrenoceptor binding sites and contractile response in four canine vascular tissues.
J Pharmacol Exp Ther
250:
1119-1124
1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta.
Life Sci
57:
159-163.
1-adrenoceptor antagonists in rat aorta.
Br J Pharmacol
118:
299-310[Medline].
1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat.
Eur J Pharmacol
305:
173-176[Medline].
This article has been cited by other articles:
![]() |
S. Guimaraes and D. Moura Vascular Adrenoceptors: An Update Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Daniel, R. D. Brown, Y. F. Wang, A. M. Low, H. Lu-Chao, and C.-Y. Kwan alpha -Adrenoceptors in Canine Mesenteric Artery Are Predominantly 1A Subtype: Pharmacological and Immunochemical Evidence J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 671 - 679. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||